Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

681. Nontypeable Haemophilus influenzae in carriage and disease: a difference in IgA1 protease activity levels. (Abstract)

Nontypeable Haemophilus influenzae in carriage and disease: a difference in IgA1 protease activity levels. Nontypeable Haemophilus influenzae strains form part of the normal flora of the human upper respiratory tract but are also implicated in a wide range of diseases. Infections caused by nontypeable H influenzae are major health and socioeconomic burdens. No single bacterial trait has been associated with disease as opposed to colonization.To compare IgA1 protease activity in nontypeable H (...) influenzae strains isolated from patients with symptomatic Haemophilus infection (sputum, cerebrospinal fluid, blood, or normally sterile tissue) vs strains from throat swabs of asymptomatic carriers and to compare iga gene carriage and variability in nontypeable H influenzae strains.Retrospective study of 63 strains (44 clinical and 19 carriage) collected between 1991 and 2000 and maintained at the Public Health Laboratory, Gwynedd General Hospital, Bangor, Wales.Levels of IgA1 protease activity

2002 JAMA

682. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, Fry-Smith A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, Fry-Smith A. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation. Health Technology Assessment 2002; 6(9): 1-87 Authors' objectives This review aims to answer the following questions: 1. How effective is zanamivir in shortening the time-course, reducing the severity of illness or preventing death in otherwise healthy adults

2002 Health Technology Assessment (HTA) Database.

683. An assessment of oseltamivir for the treatment of suspected influenza

An assessment of oseltamivir for the treatment of suspected influenza An assessment of oseltamivir for the treatment of suspected influenza An assessment of oseltamivir for the treatment of suspected influenza Husereau DR, Brady B, McGeer A Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Husereau DR, Brady B, McGeer A. An assessment (...) of oseltamivir for the treatment of suspected influenza. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2002: 12 Authors' objectives The objectives of this assessent are (1) to assess and quantify the efficacy and effectiveness of oseltamivir in individuals who are suspected of having influenza; and (2) to assess the cost-effectiveness of treating suspected influenza with oseltamivir in a primary care setting where standard treatment is no active medical intervention. Authors

2002 Health Technology Assessment (HTA) Database.

684. Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation Burls A, Clark W, Stewart T, Preston C, Bryan S, Jefferson T, Fry-Smith A Authors' objectives To assess the evidence on the effectiveness, safety, cost and cost-effectiveness of zanamivir for the treatment (...) of influenza in healthy adults and at-risk adults. Searching MEDLINE, PubMed, EMBASE, the Science Citation Index, the Cochrane Library (Issue 1), and the Glaxo Wellcome Clinical Trials Register were searched until March 2000; a list of search terms was reported in the review paper. The search strategy was extended to further sources, including NHS EED and DARE, to look for relevant economic analyses and for data to inform the economic model. Internet searches were carried out, as were handsearches of Scrip

2002 DARE.

685. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis

Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta (...) -analysis Beyer WE, Palache AM, de Jong JC, Osterhaus AD Authors' objectives To assess the differences between cold-adapted live influenza vaccine (AA-LIV) and inactivated influenza vaccine (IIV) in terms of systemic vaccine reactions, local and systemic antibody response and vaccine efficacy. Searching MEDLINE and the Cochrane Controlled Trials Register were searched from 1967 to 2000 using the following search algorithm: 'influenza' and 'vaccin*' and ('live' or 'cold adapted' or 'attenuated' or 'Ann

2002 DARE.

686. Mass mailings have little effect on utilization of influenza vaccine among Medicare beneficiaries

Mass mailings have little effect on utilization of influenza vaccine among Medicare beneficiaries Mass mailings have little effect on utilization of influenza vaccine among Medicare beneficiaries Mass mailings have little effect on utilization of influenza vaccine among Medicare beneficiaries Maglione M A, Stone E G, Shekelle P G Authors' objectives To review published and unpublished studies of mass mailings designed to increase the utilisation of influenza vaccination among Medicare (...) beneficiaries. Searching The authors searched computerised indices for published studies and the Medicare Peer Review Organization's Health Care Quality Improvement Project database for unpublished studies since 1993, the year coverage for influenza vaccination began. Study selection Study designs of evaluations included in the review The inclusion criteria specified studies using a controlled trial design. Specific interventions included in the review The inclusion criteria specified interventions using

2002 DARE.

687. Impact of universal Haemophilus influenzae Type b vaccination starting at 2 months of age in the United States: an economic analysis

Impact of universal Haemophilus influenzae Type b vaccination starting at 2 months of age in the United States: an economic analysis Impact of universal Haemophilus influenzae Type b vaccination starting at 2 months of age in the United States: an economic analysis Impact of universal Haemophilus influenzae Type b vaccination starting at 2 months of age in the United States: an economic analysis Zhou F J, Bisgard K M, Yusuf H R, Deuson R R, Bath S K, Murphy T V Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of universal Haemophilus influenzae Type b (Hib) vaccination, starting at the age of 2 months. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study

2002 NHS Economic Evaluation Database.

688. Economic evaluation of strategies for the control and management of influenza in Europe

Economic evaluation of strategies for the control and management of influenza in Europe Economic evaluation of strategies for the control and management of influenza in Europe Economic evaluation of strategies for the control and management of influenza in Europe Scuffham P A, West P A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Six strategies for the control and management of influenza were examined. There were two vaccination strategies, two chemoprophylaxis strategies and two antiviral treatments: opportunistic vaccination (OppVacc) - vaccination was performed when a patient visited a general practitioner (GP) for another reason; comprehensive vaccination (CompVacc) - GPs have vaccination records and call and recall

2002 NHS Economic Evaluation Database.

689. Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community

Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community Efficacy and cost-effectiveness of influenza vaccination of the elderly in a densely populated and unvaccinated community Wang C-S, Wang S-T, Chou P Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Influenza vaccination for the elderly was examined. The influenza vaccine was Vaxgrip 98-99 (Pasteur Merieux Connaught, France). It contained A/Beijing/262/95-like (h1N1), A/Sydney/5/97-like (H3N2) and B/Beijing/184/93-like. Type of intervention Primary prevention. Economic study type Cost

2002 NHS Economic Evaluation Database.

690. Cost-effectiveness of newer treatment strategies for influenza

Cost-effectiveness of newer treatment strategies for influenza Cost-effectiveness of newer treatment strategies for influenza Cost-effectiveness of newer treatment strategies for influenza Smith K J, Roberts M S Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Rapid testing and antiviral agents for influenza were studied. In total, seven strategies were considered in the analysis: strategy 1 was no testing or treatment; strategy 2 was oseltamivir or zanamivir treatment without testing; strategy 3 was amantadine treatment without testing; strategy 4 was rimantadine treatment without testing; strategy 5 was testing then the treatment of positive tests with oseltamivir or zanamivir; strategy 6 was testing then amantadine

2002 NHS Economic Evaluation Database.

691. Economic analysis of influenza vaccination and antiviral treatment for healthy working adults

Economic analysis of influenza vaccination and antiviral treatment for healthy working adults Economic analysis of influenza vaccination and antiviral treatment for healthy working adults Economic analysis of influenza vaccination and antiviral treatment for healthy working adults Lee P Y, Matchar D B, Clements D A, Huber J, Hamilton J D, Peterson E D Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains (...) a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Several strategies for influenza vaccination and antiviral treatment were examined. These were: no vaccination and no intervention (base-case); no vaccination and treatment with zanamivir; no vaccination and treatment with rimantadine; no vaccination and treatment with oseltamivir; vaccination and no intervention

2002 NHS Economic Evaluation Database.

692. Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria

Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria Cost-benefit evaluation of influenza vaccination in the elderly in the Italian region of Liguria Gasparini R, Lucioni C, Lai P, Maggioni P, Sticchi L, Durando P, Morelli P, Comino I, Calderisi S, Crovari P Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined influenza vaccination in the elderly. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population consisted of individuals older than 65 years. Setting The setting was unclear, but it is likely

2002 NHS Economic Evaluation Database.

693. A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK

A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK A model to estimate the cost benefit of an occupational vaccination programme for influenza with Influvac in the UK Das Gupta R, Guest J F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each (...) abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The introduction of an occupational vaccination programme for influenza with an inactivated influenza sub-unit vaccine (Influvac) was examined. Type of intervention Primary prevention. Economic study type Cost-benefit analysis. Study population The study population comprised a hypothetical cohort

2002 NHS Economic Evaluation Database.

694. Clinical and economic evaluation of rapid influenza A virus testing in nursing homes in Calgary, Canada Full Text available with Trip Pro

Services). The laboratory analysed all nasopharyngeal samples within 2 hours of their receipt (24 hours/day and 7 days/week) using the Directigen Flu-A assay, and immediately relayed the results by telephone to the nursing home. The Directigen Flu-A assay is an enzyme immunoassay that detects influenza A virus nucleoprotein. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised men and women who met the definition (...) Clinical and economic evaluation of rapid influenza A virus testing in nursing homes in Calgary, Canada Clinical and economic evaluation of rapid influenza A virus testing in nursing homes in Calgary, Canada Clinical and economic evaluation of rapid influenza A virus testing in nursing homes in Calgary, Canada Church D L, Davies H D, Mitton C, Semeniuk H, Logue M, Maxwell C, Donaldson C Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion

2002 NHS Economic Evaluation Database.

695. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years

Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years Nichol K L, Goodman M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The vaccination of healthy persons aged between 65 and 74 years for influenza was studied. Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised healthy persons aged between 65 and 74 years. Patients were considered to be eligible if they had no diagnosis in the preceding year of heart disease

2002 NHS Economic Evaluation Database.

696. Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. (Abstract)

Contribution of influenza and respiratory syncytial virus to community cases of influenza-like illness: an observational study. Respiratory syncytial virus (RSV) is an important cause of lower-respiratory-tract infection in children and elderly people, but its effect in other age-groups is uncertain. We did a community-based observational study of RSV infection in community-dwelling individuals of all ages who presented to general practices in the UK with influenza-like illnesses during three (...) successive winters (1995-96, 1996-97, and 1997-98).Nasopharyngeal swabs routinely submitted for virological surveillance were examined by multiplex reverse transcription PCR for influenza A and B viruses and RSV A and B, and findings were related to the clinical incidence of influenza-like illness and acute bronchitis at that time. RSV strains identified were compared with those obtained from hospital admissions.480 RSV and 709 influenza viruses were identified from a total of 2226 swabs submitted. Both

2001 Lancet

697. Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites? (Abstract)

Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites? Substantial racial disparities exist in use of some health services. Whether managed care could reduce racial disparities in the use of preventive services is not known.To determine whether the magnitude of racial disparity in influenza vaccination is smaller among managed care enrollees than among those with fee-for-service insurance.The 1996 Medicare Current Beneficiary Survey (...) of a US cohort of 13 674 African American and white Medicare beneficiaries with managed care and fee-for-service insurance.Percentage of respondents (adjusted for sociodemographic characteristics, clinical comorbid conditions, and care-seeking attitudes) who received influenza vaccination and magnitude of racial disparity in influenza vaccination, compared among those with managed care and fee-for-service insurance.Eight percent of the beneficiaries were African American and 11% were enrolled

2001 JAMA

698. Treating influenza by medication – Zanamivir</a>

Treating influenza by medication – Zanamivir Treating influenza by medication – Zanamivir We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Swedish Agency for Health Technology Assessment and Assessment of Social Services Treating influenza by medication – Zanamivir Share: Reading time approx. 4 minutes This document was published more than 2 years ago. The nature of the evidence may have changed. Findings by SBU Alert (...) This is a translation of version 1, published on January 12, 2001. The information and references added on May 4, 2004 is not incorporated in this English translation. Method Zanamivir (Relenza) is an antiviral drug indicated for treatment of influenza. The drug was approved in Sweden in February 1999. Zanamivir is a powder for administration to the respiratory tract by oral inhalation via a Diskhaler. For treatment to be effective, it must be initiated within 48 hours of the onset of influenza symptoms

2001 Swedish Council on Technology Assessement

699. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. (Abstract)

Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. Influenza virus is easily spread among the household contacts of an infected person, and prevention of influenza in household contacts can control spread of influenza in the community.To investigate the efficacy of oseltamivir in preventing spread of influenza to household contacts of influenza-infected index cases (ICs).Randomized, double-blind, placebo-controlled study conducted at 76 (...) centers in North America and Europe during the winter of 1998-1999.Three hundred seventy-seven ICs, 163 (43%) of whom had laboratory-confirmed influenza infection, and 955 household contacts (aged >/=12 years) of all ICs (415 contacts of influenza-positive ICs).Household contacts were randomly assigned by household cluster to take 75 mg of oseltamivir (n = 493) or placebo (n = 462) once daily for 7 days within 48 hours of symptom onset in the IC. The ICs did not receive antiviral treatment.Clinical

2001 JAMA Controlled trial quality: predicted high

700. The safety of inactivated influenza vaccine in adults and children with asthma. (Abstract)

The safety of inactivated influenza vaccine in adults and children with asthma. Influenza causes substantial morbidity in adults and children with asthma, and vaccination can prevent influenza and its complications. However, there is concern that vaccination may cause exacerbations of asthma.To investigate the safety of the inactivated trivalent split-virus influenza vaccine in adults and children with asthma, we conducted a multicenter, randomized, double-blind, placebo-controlled, cross-over (...) of asthma in the two weeks after the injections.The frequency of exacerbations of asthma was similar in the two weeks after the influenza vaccination and after placebo injection (28.8 percent and 27.7 percent, respectively; absolute difference, 1.1 percent; 95 percent confidence interval, -1.4 percent to 3.6 percent). The exacerbation rates were similar in subgroups defined according to age, severity of asthma, and other factors. Among symptoms thought to be associated with the injection, only body

2001 NEJM Controlled trial quality: predicted high